磁共振引导再程放疗用于前列腺内或前列腺床局部复发:前瞻性注册研究初步结果
这项前瞻性注册研究评估了立体定向磁共振成像(MRI)引导放疗用于原发性放疗后前列腺内或前列腺床孤立复发的可行性。20例患者纳入,中位随访至少6个月,急性毒性以1-2级泌尿和肠道反应为主,初始计划均满足肿瘤覆盖目标,7例(35%)进行了计划适应,肿瘤覆盖较预测计划提高3.7%(P = .0001),全体生化控制率为75%(15/20)。
要点
- MRI引导再程放疗用于前列腺内或前列腺床孤立复发初步显示安全性良好。
- 35%患者需要计划适应,适应后肿瘤覆盖提高3.7%且不增加危及器官剂量。
- 全体生化控制率75%(15/20),包括4例接受雄激素剥夺治疗者。
核心结论
- MRI引导再程放疗用于前列腺内或前列腺床孤立复发看似安全,剂量学结果优异。
研究设计与样本
- 前瞻性注册研究,纳入原发性外照射或前列腺近距离治疗后无区域或远处扩展的孤立复发患者,共20例。
- MRI模拟采用173秒Fast Imaging with Steady state Precession(TrueFISP)序列,基于多模态图像勾画大体肿瘤体积。
- 初始治疗计划为27.5 Gy分5次至38.7 Gy分9次,每次治疗时必要时进行计划适应。
- 主要终点为急性毒性(常见不良事件评价标准v5.0),次要终点包括适应治疗对靶区覆盖的影响、晚期毒性和肿瘤学事件。
主要发现
- 至少6个月随访后,报告2级排尿困难(基线1级,n=1)、2级多尿(n=1)、1级尿失禁(n=1)、1级尿痛(n=2)、1级腹泻(n=1)。
- 所有初始治疗计划均满足肿瘤覆盖目标,计划靶区95%平均值为95.7%。
- 无计划超过膀胱和直肠剂量约束,但8例因尿道靠近计划靶区而超过尿道剂量约束。
- 7例(35%)进行了初始计划适应,肿瘤覆盖较预测计划提高3.7%(P = .0001),危及器官剂量未增加。
- 全体生化控制率为75%(15/20例),包括4例接受雄激素剥夺治疗的患者。
关键数值与推荐
- 初始治疗计划剂量范围为27.5 Gy分5次至38.7 Gy分9次。
- 计划靶区95%平均值为95.7%。
- 肿瘤覆盖较预测计划提高3.7%(P = .0001)。
- 生化控制率75%(15/20例)。
临床怎么用
- 对于原发性放疗后前列腺内或前列腺床孤立复发,可考虑MRI引导立体定向再程放疗。
- 治疗中需关注尿道剂量约束,因靶区靠近尿道可能导致超限。
- 每次治疗时根据解剖变化进行计划适应可能改善靶区覆盖而不增加危及器官剂量。
局限性
- 样本量小(20例),随访时间短(至少6个月)。
- 为初步注册研究结果,需更大样本和更长随访验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This prospective registry study evaluated the feasibility of stereotactic magnetic resonance imaging (MRI)-guided radiation therapy for the local treatment of isolated prostate cancer recurrence within the gland or prostate bed after primary radiation therapy. METHODS AND MATERIALS: Patients with isolated recurrence without any regional or distant extension after treatment by external radiation therapy of the prostate gland/bed or by prostate brachytherapy were included. A 173-second Fast Imaging with Steady state Precession (TrueFISP) sequence was used for MRI simulation, and the gross tumor volume was delineated using multimodal images. The initial treatment plan varied from 27.5 Gy in 5 fractions to 38.7 Gy in 9 fractions and was adapted at each session, if necessary. The primary endpoint was acute toxicities (according to the Common Terminology Criteria for Adverse Events v5.0 criteria). Secondary endpoints were the effects of the adaptive treatment on target volume coverage, late toxicities, and oncologic events. RESULTS: Twenty patients were included. After a minimum follow-up of 6 months, grade 2 dysuria (from grade 1 at baseline; n = 1), grade 2 polyuria (n = 1), grade 1 urinary incontinence (n = 1), grade 1 urinary pain (n = 2), and grade 1 diarrhea (n = 1) were reported.All initial treatment plans met the tumor coverage objectives, with a mean 95% planning target volume value of 95.7%. No plan exceeded the bladder and rectum dose constraints, but 8 exceeded the urethra dose constraints because of urethra proximity to the planning target volume. The initial plan was adapted in 7 patients (35%). The tumor coverage improved by 3.7% compared with the predicted plan (P = .0001) without increase in the dose to organs at risk. The biochemical control rate for the whole cohort was 75% (15/20 patients) including the 4 patients who received androgen-deprivation therapy. CONCLUSIONS: MRI-guided reirradiation for isolated recurrence within the prostate or in the prostate bed appears to be safe with excellent dosimetric results.
引用
- Michalet M, Riou O, Valdenaire S, et al. Magnetic Resonance-Guided Reirradiation for Local Recurrence Within the Prostate or in the Prostate Bed: Preliminary Results of a Prospective Registry Study. Adv Radiat Oncol. 2021. PMID: 34646967. doi:10.1016/j.adro.2021.100748
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。